

2 0 1 5  
A  
8<sup>th</sup> PARIS  
HEPATITIS  
CONFERENCE

**12 & 13 January 2015**

**PARIS** - Palais des Congrès

---

**International Conference on the Management  
of Patients with Viral Hepatitis**

**Organised by Pr Patrick Marcellin**

**Organising Committee:**

**Pr Tarik Asselah,**

**Dr Nathalie Boyer, Dr Emilie Estrabaud,**

**Dr Michelle Martinot-Peignoux, Dr Monelle Muntlak**

**Hôpital Beaujon, APHP - UMR 1149 Inserm, CRI - Université Paris-Diderot**

---

**[www.aphc.info](http://www.aphc.info)**



Follow us on Twitter: @PHC\_off #PHC2015



Dear colleagues,

**We are pleased to announce that the 8<sup>th</sup> Paris Hepatitis Conference (PHC) will take place on January 12 and 13, 2015.**

As it has in the past, the meeting will provide state of the art information on the management of patients with hepatitis B and C presented by renowned international experts who will discuss the most recent leading edge data and their clinical applications.

This year the meeting will provide an update on the spectacular progress made in the treatment of hepatitis C with IFN free regimens using polymerase, NS5A and protease inhibitors. The advantages of these combinations are considerable: they are well tolerated and effective in all genotypes after a shorter duration (nearly 100% SVR with 12 weeks of treatment). Indeed, because of these benefits the issue is now facilitating access to treatment in more patients with a realistic objective of eradicating hepatitis C.

However, these treatments are not yet available in most countries. Moreover, first or second-generation triple therapies have just been introduced in many countries. Therefore the optimal strategies for different types of patients, taking into account several factors (severity of liver disease, genotype, treatment status...) must be determined in relation to available resources and drugs.

The PHC 2015 will also spend a full day addressing important issues related to hepatitis B. We will discuss long-term efficacy and tolerance in patients receiving the most potent available antivirals. Recent studies with up to 8 years of treatment reported a favorable outcome with a regression of fibrosis and a decrease in the incidence of HCC in treated patients without viral resistance. We will also address the role of quantification of HBsAg that appears to be a new tool to assess the severity of the disease and the response to therapy. The optimal management of difficult populations will be extensively discussed: co-infections, cirrhosis...

As in previous PHCs, we will privilege interactive discussions and specific lunch workshops addressing the management of real life patients. Indeed, the ultimate goal of the PHC 2015 is to review the most current knowledge and discuss their therapeutic implications with the most experienced experts to provide optimal therapy and the best chance of cure to as many patients as possible, worldwide.

I look forward to welcoming you to Paris,

**Professor Patrick Marcellin**  
President of the 8<sup>th</sup> Paris Hepatitis Conference

# HEPATITIS C

## 08.30 Introduction: Treatment of hepatitis C: towards the eradication?

*Patrick Marcellin (France)*

## 08.40 - 09.00 State of the art lecture

**Chairman:** *Tarik Asselah (France)*

- Treatment of hepatitis C today and tomorrow

*Antonio Craxi (Italy)*

## 09.00 - 10.00 How to optimize current therapy of G1 patients

**Chairmen:** *Nezam Afdhal (USA) and Stanislas Pol (France)*

- 09.00 ■ PEG IFN based therapy with 2nd wave DAAs

*Donald Jensen (USA)*

- 09.15 ■ Shortened therapy with IFN-based therapy

*Thomas Berg (Germany)*

- 09.30 ■ Predictors of response to IFN-based therapy

*Lawrence Serfaty (France)*

- 09.45 ■ Round table discussion

☕ 10.00 - 10.20 Coffee break

## 10.20 - 11.20 How to optimize current therapy of non G1 patients

**Chairmen:** *Jake Liang (USA) and Stefan Zeuzem (Germany)*

- 10.20 ■ Genotype 2, what's new?

*Marc Bourlière (France)*

- 10.35 ■ Why genotype 3 is difficult to cure?

*Graham Foster (UK)*

- 10.50 ■ Genotype 4, finally cured?

*Imam Waked (Egypt)*

- 11.05 ■ Round table discussion

## 11.20 - 12.30 How to improve access to therapy? Around the World table *Patrick Marcellin (France)*

**Chairmen:** *Massimo Colombo (Italy), Michael Fried (USA)*

**Speakers:** *Victor De Ledinghen (France), Gamal Esmat (Egypt), Rafael Esteban (Spain), Robert Flisiak (Poland), Vasily Isakov (Russia), Michael Manns (Germany), Raymundo Parana (Brazil)*

## 12.30 - 14.30 Lunch Workshops

### 14.30 - 15.35 Special populations

**Chairs:** *Maria Buti (Spain) and François Durand (France)*

- 14.30 ■ Patients with comorbidities

*Savino Bruno (Italy)*

- 14.45 ■ DAAs and transplant patients

*Didier Samuel (France)*

- 15:00 ■ HIV co-infected patients

*Juergen Rockstroh (Germany)*

- 15:15 ■ Round table discussion

☕ 15:35 - 16:00 Coffee break

## 16.00 - 16.50 New therapeutic strategies

**Chairmen:** *Ira Jacobson (USA) and Michael Manns (Germany)*

- 16.00 ■ INF-free therapy in naïve patients

*Tarik Asselah (France)*

- 16.15 ■ INF-free therapy in experienced patients

*David Nelson (USA)*

- 16.30 ■ Round table discussion

## 16.50 - 17.25 Controversy: Cure of HCV-related liver disease?

**Chairman:** *Eugene Schiff (USA)*

- 16.50 ■ No: *Mitchell Shiffman (USA)*

- 17.00 ■ Yes: *Yves Benhamou (France)*

- 17.10 ■ Discussion

## 17.25 - 17.40 Hepatitis C: A public health priority

*Bernard Kouchner (France)*

## 17.40 - 17.50 Take home messages

*Tarik Asselah (France)*

## 17.50 - 17.55 Conclusion

*Patrick Marcellin (France)*

19.30 Congress dinner

# HEPATITIS B

08.30 Introduction: is HBV controlled? *Patrick Marcellin (France)*

## 08.40 - 10.00 The control of HBV related liver disease

*Chairmen: Laurent Castera (France) and Fabien Zoulim (France)*

08.40 ■ Cirrhosis reversibility: who and why? *Pierre Bedossa (France)*

08.55 ■ HBsAg quantification to manage patients *Michelle Martinot-Peignoux (France)*

09.10 ■ What have we learned from HBV clinical cohorts? *Jia-Hong Kao (Taiwan)*

09.30 ■ Round table discussion

☕ 10.00 - 10.30 Coffee break

## 10.30 - 12.00 Optimal therapy of chronic hepatitis B

*Chairmen: Adrian Gadano (Argentina) and Ji Dong Jia (China)*

10.30 ■ How do I treat my HBeAg-positive patients? *Georgios Papatheodoridis (Greece)*

10.50 ■ How do I treat my HBeAg-negative patients? *Pietro Lampertico (Italy)*

11.10 ■ HBV: perspectives for treatment *Jorg Petersen (Germany)*

11.30 ■ Round table discussion

## 12.00 - 12.30 State of the art lecture

*Chairman: Tarik Asselah (France)*

■ HBV and the immune response

*Carlo Ferrari (Italy)*

## 12.30 - 14.30 Lunch Workshops

## 14.30 - 15.00 State of the art lecture and Award

*Chairman: Patrick Marcellin (France)*

■ Viral hepatitis: the past and the future

*Eugene Schiff (USA)*

## 15.00 - 16.30 End-stage liver disease is a multifaceted condition

*Chairmen: Adrian Di Bisceglie (USA) and Richard Moreau (France)*

15.00 ■ Acute-on-chronic liver failure is a new clinical entity *Vicente Arroyo (Spain)*

15.20 ■ Management of hepatocellular carcinoma in 2015 *Massimo Colombo (Italy)*

15.40 ■ The coagulation system in end-stage liver disease *Dominique Valla (France)*

16.00 ■ Round table discussion

## 16.30 Take home messages

*Tarik Asselah (France)*

## 16.40 Conclusion

*Patrick Marcellin (France)*

16.45 Closing session

# PROGRAMME OF THE LUNCH WORKSHOPS

For people not registered to the lunch workshops, regular lunches are also organized Level 4

January 12<sup>th</sup> from 12:30 to 14:30

## Room 253

### 1. The long term impact of treatment on the outcome of liver disease

*Jia-Horng Kao (Taiwan),  
Nurdan Tozun (Turkey)*

## Room 241

### 2. First line therapy of hepatitis B: interferon or analogues?

*Rafael Esteban (Spain),  
Cihan Yurdaydin (Turkey)*

## Room 242 B

### 3. Clinical applications of HBsAg quantification

*Philippe Halfon (France),  
Michelle Martinot-Peignoux (France),  
Philippe Sogni (France)*

## Room 242 A

### 4. Staging of fibrosis: liver biopsy or indirect markers?

*Pierre Bedossa (France),  
Victor De Ledinghen (France)*

## Room 252 B

### 5. Treatment of HCV cirrhosis and transplanted patients

*Rajiv Jalan (UK),  
Didier Samuel (France),  
Dominique Valla (France)*

## Room 251

### 6. HIV-HCV coinfections

*Juergen Rockstroh (Germany),  
Mark Sulkowski (USA)*

## Room 252 A

### 7. Interferon ou analogue ? (French speaking lunch workshop)

*Denis Ouzan (France),  
Christian Trépo (France),  
Jean-Pierre Zarski (France)*

## Room 243

### 8. Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop)

*Mustapha Benazzouz (Morocco),  
Nathalie Boyer (France),  
Jean-François Cadranel (France),  
Adriana Popescu (Romania)*

January 13<sup>th</sup> from 12:30 to 14:30

## Room 242 A

### 1. How to optimize treatment in G1 naive patients?

*Antonio Craxi (Italy),  
Raluca Pais (France),  
Vlad Ratziu (France)*

## Room 251

### 2. HCV eradication with DAAs?

*Emilie Estrabaud (France),  
Michael Fried (USA),  
Massimo Levrero (Italy)*

## Room 252 B

### 3. How to manage relapsers and non-responders to PEG IFN + RBV therapy

*Peter Ferenci (Austria),  
Andrzej Horban (Poland),  
Konstantin Zhdanov (Russia)*

## Room 252 A

### 4. Triple therapy with telaprevir or boceprevir: management of side effects

*Donald Jensen (USA),  
Markus Peck-Radosavljevic (Austria),  
Petr Urbánek (Czech Republic)*

## Room 241

### 5. Future therapeutic strategies with direct acting antivirals

*Nezam Afdhal (USA),  
Yves Benhamou (France)*

## Room 253

### 6. How to optimize treatment in G4 patients?

*Tarik Asselah (France),  
Gamal Esmat (Egypt)*

## Room 242 B

### 7. Traitements des patients rechuteurs et non répondeurs (French speaking lunch workshop)

*Jean-Pierre Bronowicki (France),  
Christophe Hézode (France),  
Badreddine Kilani (Tunisia),  
Vincent Leroy (France)*

## Room 243

### 8. Comment optimiser le traitement des malades naïfs ? (French speaking lunch workshop)

*Nabil Debzi (Algeria),  
Daniel Dhumeaux (France),  
Philippe Mathurin (France),  
Mihai Voiculescu (Romania)*

# GENERAL INFORMATION

## CONFERENCE DATES AND VENUE

From Monday 12<sup>th</sup>  
to Tuesday 13<sup>th</sup> January 2015  
At the "Palais des Congrès"  
2, place de la Porte Maillot  
75017 Paris – France  
**Metro and RER station:**  
"Porte Maillot"

## CONFERENCE REGISTRATION DESK

12<sup>th</sup> & 13<sup>th</sup> January, from 7:30 am.  
Welcome desks are organized on level 2 of the Palais de Congrès in Foyer Bleu next to the Amphitheatre Bleu. You will be able to retrieve your access badge, congress bag and proceedings.

## CONGRESS OFFICE

Quadrature Santé / PHC 2015  
43 rue des Tilleuls  
92100 Boulogne-Billancourt  
Phone: +33 1 41 10 46 65  
Fax: +33 1 41 10 46 69  
Contact: [contact@phc-congress.com](mailto:contact@phc-congress.com)  
[www.aphc.info](http://www.aphc.info)

## CONGRESS HOTELS

**Hyatt Regency Paris Étoile**  
3 place du Général Koenig  
75017 Paris  
Tel : +33 (0) 1 40 68 12 34

**Méridien Etoile Hotel**  
81 boulevard Gouvion St-Cyr  
75 017 Paris  
Tel: +33 (0) 1 40 68 34 34

## CONGRESS DINNER

Monday 12<sup>th</sup> January at the  
Pré Catalan  
Bois de Boulogne,  
Route de Suresnes, 75016 Paris  
Buses will leave from the Palais des  
Congrès from 7:00 p.m.  
Dress code : cocktail attire

## CME CONTINUOUS MEDICAL EDUCATION ACCREDITATION

The "APHC" is accredited by the European  
Accreditation Council for Continuing  
Medical Education (EACCME) to provide  
the following CME activity for medical  
specialists.

The 8th Paris Hepatitis Conference is  
designated for a maximum of (or "for up to")  
11 European CME credits (ECMEC).

## LIVER INTERNATIONAL

The PHC Liver International Supplement is  
available online at the following address:  
<http://blackwellpublishing.com>

## LUNCHESS

2 types of lunches are organised  
each day:

- *Lunch Workshops* (Level 2).  
The number of seats is limited.
- *Regular lunches* are organised in Salon  
Arc en Ciel (Level 4).

## METRO and RER

The metro station (line 1) and RER station  
(line C) are located on level -1 of the  
Palais des Congrès: Porte Maillot station.  
The Conference will be held in  
Amphitheatre Bleu on level 2.

## OFFICIAL LANGUAGE

The official language  
of the conference is English.

